Allworth Financial LP Vir Biotechnology, Inc. Transaction History

Allworth Financial LP

$16.1 Billion
Q3 2024

A detailed history of Allworth Financial LP transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 3,642 shares of VIR stock, worth $33,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,642

Previous 3,748 2.83%

Holding current value

$33,506

Previous $33,000 18.18%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	SELL	$7.26 - $10.7 $769 - $1,134	-106 Reduced 2.83%	3,642 $27,000
Q2 2024 Jul 23, 2024	SELL	$7.63 - $12.66 $1,686 - $2,797	-221 Reduced 5.57%	3,748 $33,000
Q1 2024 Apr 25, 2024	SELL	$8.6 - $11.9 $361 - $499	-42 Reduced 1.05%	3,969 $40,000
Q4 2023 Jan 24, 2024	BUY	$7.76 - $10.29 $1,458 - $1,934	188 Added 4.92%	4,011 $40,000
Q3 2023 Oct 31, 2023	BUY	$9.14 - $24.62 $9 - $24	1 Added 0.03%	3,823 $35,000
Q2 2023 Jul 18, 2023	SELL	$23.2 - $27.29 $15,961 - $18,775	-688 Reduced 15.25%	3,822 $93,000
Q1 2023 Apr 18, 2023	SELL	$22.26 - $30.85 $15,826 - $21,934	-711 Reduced 13.62%	4,510 $104,000
Q4 2022 Jan 13, 2023	BUY	$19.96 - $28.22 $59 - $84	3 Added 0.06%	5,221 $0
Q3 2022 Oct 18, 2022	BUY	$18.26 - $31.1 $1,771 - $3,016	97 Added 1.89%	5,218 $101,000
Q2 2022 Jul 13, 2022	BUY	$19.08 - $26.7 $400 - $560	21 Added 0.41%	5,121 $130,000
Q1 2022 Apr 22, 2022	BUY	$21.19 - $40.01 $104,170 - $196,689	4,916 Added 2671.74%	5,100 $131,000
Q4 2021 Jan 21, 2022	BUY	$30.97 - $54.03 $5,698 - $9,941	184 New	184 $8,000
Q2 2021 Aug 02, 2021	SELL	$38.75 - $51.0 $2,518 - $3,315	-65 Closed	0 $0
Q1 2021 Apr 29, 2021	BUY	$26.34 - $83.07 $1,712 - $5,399	65 New	65 $3,000

Others Institutions Holding VIR

# of Institutions

219

Shares Held

87.4M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.22B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.

Account

Allworth Financial LP Vir Biotechnology, Inc. Transaction History